Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Blueprint Medicines Corp | bpmc-20170630ex312a9a5a7.htm |
| EX-31.1 - EX-31.1 - Blueprint Medicines Corp | bpmc-20170630ex311156b9e.htm |
| EX-10.2 - EX-10.2 - Blueprint Medicines Corp | bpmc-20170630ex102cae605.htm |
| EX-10.1 - EX-10.1 - Blueprint Medicines Corp | bpmc-20170630ex101b7ab61.htm |
| 10-Q - 10-Q - Blueprint Medicines Corp | bpmc-20170630x10q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Blueprint Medicines Corporation (the “Company”) for the period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
|
Date: August 2, 2017 |
By: |
/s/ Jeffrey W. Albers |
|
|
|
Jeffrey W. Albers President and Chief Executive Officer |
|
|
|
(Principal Executive Officer) |
|
Date: August 2, 2017 |
By: |
/s/ Michael Landsittel |
|
|
|
Michael Landsittel Vice President of Finance |
|
|
|
(Principal Financial and Accounting Officer) |